Merck, Moderna Detail Potential Skin Cancer Vaccine Progress

December 14, 2022by Tom Murphy, Associated Press
Merck, Moderna Detail Potential Skin Cancer Vaccine Progress
A sign marks an entrance to a Moderna building in Cambridge, Mass., on Monday, May 18, 2020. (AP Photo/Bill Sikes, File)

Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.

The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.

The drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in survival before the cancer returned in patients with advanced melanoma.

“We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” Moderna CEO Stéphane Bancel told CNBC Tuesday morning.

Phase 3 is generally the largest and most expensive stage of clinical research before regulators review a potential drug for approval.

Moderna developed one of the most popular vaccines used to protect patients against COVID-19, and the drugmaker brought in more than $3 billion from its Spikevax in this year’s third quarter.

But vaccine use has slowed and Moderna depends on Spikevax for nearly all its revenue.

Like Spikevax, the potential skin cancer vaccine uses mRNA technology. It trains a patient’s immune system to recognize and respond specifically to mutations in the DNA of the patient’s tumor.

In a mid-stage clinical trial involving 157 patients, researchers compared the vaccine-Keytruda combination with Keytruda alone.

Keytruda, Merck’s top seller, primes the body’s immune system to detect and fight tumor cells. Regulators have approved it to treat several types of cancer.

The patient group that took the potential vaccine and Keytruda saw a 44% reduction in the risk of death or the cancer returning, the companies said.

The treatments continued for about a year in both groups unless the disease came back or side effects became too severe.

Merck and Moderna expect to start a phase 3 study next year, and the companies say they intend to expand their approach to other tumor types.

Merck and Moderna established an agreement to work together in 2016, and the companies plan to share costs and profits in their collaboration. Merck also paid Moderna $250 million.

Shares of Cambridge, Massachusetts-based Moderna Inc. soared 23% to top $200 in midday trading while broader indexes climbed. Kenilworth, New Jersey-based Merck & Co. climbed less than 1%.

A+
a-
  • skin cancer
  • vaccine
  • In The News

    Health

    Voting

    Health

    Gov. Jay Inslee Says Washington Will Make Clear Hospitals Must Provide Emergency Abortions

    SEATTLE (AP) — Gov. Jay Inslee on Tuesday said Washington will spell out in state law that hospitals must provide... Read More

    SEATTLE (AP) — Gov. Jay Inslee on Tuesday said Washington will spell out in state law that hospitals must provide abortions if needed to stabilize patients, a step that comes as the U.S. Supreme Court is expected to rule this month on whether conservative states can bar abortions... Read More

    June 11, 2024
    by Dan McCue
    Federal Judge Tosses Florida Ban on Gender-Affirming Care

    TALLAHASSEE, Fla. — A Florida law banning gender-affirming health care for transgender minors and restricting access to care for some... Read More

    TALLAHASSEE, Fla. — A Florida law banning gender-affirming health care for transgender minors and restricting access to care for some transgender adults is unconstitutional, a federal judge ruled Tuesday. The law, which was signed by Florida Gov. Ron DeSantis in May of last year, barred doctors... Read More

    June 11, 2024
    by Dan McCue
    DC to Open Final Application Period for Medical Cannabis Dispensaries

    WASHINGTON — The District of Columbia will open what it is calling the “final” application period for medical cannabis license... Read More

    WASHINGTON — The District of Columbia will open what it is calling the “final” application period for medical cannabis license applications on July 1. In all, 33 retail licenses and two internet licenses will be available to non-social equity applicants, with the application period slated to... Read More

    Film Panel to Discuss Loneliness Epidemic and Importance of Social Connection

    WASHINGTON — Sen. Chris Murphy, D-Conn., and U.S. Surgeon General Dr. Vivek Murthy are set to host a film panel... Read More

    WASHINGTON — Sen. Chris Murphy, D-Conn., and U.S. Surgeon General Dr. Vivek Murthy are set to host a film panel discussion on the dangers of loneliness in American society Tuesday evening, following a showing of the documentary “Join or Die” at the Capitol Visitor Center. Created... Read More

    Community Health Centers' New Crisis: The Need for Backup Power

    HEALDSBURG, Calif. (AP) — The 2017 Tubbs Fire, which killed 22 people and destroyed 5,600 buildings, was already a stressful time... Read More

    HEALDSBURG, Calif. (AP) — The 2017 Tubbs Fire, which killed 22 people and destroyed 5,600 buildings, was already a stressful time at Alliance Medical Center’s clinic here, as workers who picked grapes in the nearby vineyards streamed into the nonprofit community health center with burns, symptoms of... Read More

    FDA and DOJ Pledge More Cooperation on Illegal E-Cigarettes Ahead of Congressional Hearing

    WASHINGTON (AP) — Federal health regulators and law enforcement officials on Monday vowed to work more closely to stop sales... Read More

    WASHINGTON (AP) — Federal health regulators and law enforcement officials on Monday vowed to work more closely to stop sales of illegal electronic cigarettes, which have grown into a multibillion-dollar business in the U.S. while skirting government oversight. The Food and Drug Administration said it would launch a... Read More

    News From The Well
    scroll top